NYSE:ATNM

Actinium Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy ATNM

*Your capital is at risk

$1.11

-0.0500 (-4.31%)

At Close: Jun 04, 2026

The Schall Law Firm Is Looking Into Actinium Pharmaceuticals Inc For Possible Securities Fraud And Investors With Losses Are Urged To Join The Inquiry

11:00am, Sunday, 22'nd Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

Actinium Pharmaceuticals, Inc. May Have Violated Securities Laws And The Schall Law Firm Encourages Impacted Shareholders To Reach Out

11:00am, Saturday, 21'st Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

10:00am, Saturday, 21'st Sep 2024

NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investor

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

11:00am, Friday, 20'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

08:00am, Friday, 20'th Sep 2024

Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches SIE

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

07:45pm, Thursday, 19'th Sep 2024

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investor

The Schall Law Firm Is Looking Into Actinium Pharmaceuticals, Inc.'s Possible Securities Law Violations And Stockholders With Losses Should Reach Out

11:00am, Thursday, 19'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

Actinium Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm

11:00am, Wednesday, 18'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

08:45pm, Tuesday, 17'th Sep 2024

NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM).

The Schall Law Firm Seeks Shareholder Participation In An Inquiry Into Actinium Pharmaceuticals, Inc. For Violating Securities Laws

11:00am, Tuesday, 17'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

Actinium Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

11:00am, Monday, 16'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

12:00pm, Sunday, 15'th Sep 2024

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investor

The Schall Law Firm Wants Shareholders To Partake In An Inquiry Into Actinium Pharmaceuticals, Inc. For Securities Related Infractions

11:00am, Sunday, 15'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

Actinium Pharmaceuticals Inc Is Being Investigated By The Schall Law Firm For Possible Fraud And Investors With Losses Should Reach Out

11:00am, Saturday, 14'th Sep 2024

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pha

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM

07:00pm, Friday, 13'th Sep 2024

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investor

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by